Bond Sale for Acquisition: Abbott Laboratories announced a $20 billion bond sale to fund the acquisition of Exact Sciences, igniting debate across social media platforms. Investors weighed the merits of bolstering cancer screening capabilities against the backdrop of rising debt in a tightening financial landscape. Recent FY2025 earnings, with revenue up 5.7% to $44.3 billion but net income halved by taxes, added context to the strategic pivot.
Growth Offsets Challenges: Medical devices revenue soared 12.6% to $21.4 billion, offsetting a 4.3% decline in diagnostics from fading COVID tests. Social media chatter highlighted optimism around oncology expansion via Exact Sciences while scrutinizing the deal's integration risks. Traders noted increased options volume as signs of near-term interest.
Strategic Bet Analysis: Participants questioned if the massive financing underscores confidence or overreach amid moderating growth. Discussions blended enthusiasm for Abbott's diagnostics evolution with calls for fiscal prudence. Sentiment remains focused on execution post-deal.
Note: This discussion summary was generated from an AI condensation of post data.
Abbott Laboratories Insider Trading Activity
Abbott Laboratories insiders have traded $ABT stock on the open market 4 times in the past 6 months. Of those trades, 3 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $ABT stock by insiders over the last 6 months:
- ROBERT B FORD (CHAIRMAN AND CEO) purchased 18,800 shares for an estimated $2,013,966
- DANIEL J STARKS has made 2 purchases buying 10,000 shares for an estimated $1,087,331 and 0 sales.
- ERIC SHROFF (Senior Vice President) sold 1,586 shares for an estimated $203,042
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Abbott Laboratories Revenue
Abbott Laboratories had revenues of $11.5B in Q4 2025. This is an increase of 4.42% from the same period in the prior year.
You can track ABT financials on Quiver Quantitative's ABT stock page.
Abbott Laboratories Congressional Stock Trading
Members of Congress have traded $ABT stock 10 times in the past 6 months. Of those trades, 4 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $ABT stock by members of Congress over the last 6 months:
- REPRESENTATIVE THOMAS H. KEAN, JR. purchased up to $15,000 on 01/29.
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 1 purchase worth up to $15,000 on 11/18 and 1 sale worth up to $15,000 on 12/19.
- REPRESENTATIVE JULIE JOHNSON has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 12/18, 11/13.
- REPRESENTATIVE JULIA LETLOW sold up to $15,000 on 12/08.
- REPRESENTATIVE BYRON DONALDS has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 12/04.
- REPRESENTATIVE RICHARD MCCORMICK purchased up to $15,000 on 11/05.
- REPRESENTATIVE RICK LARSEN purchased up to $15,000 on 10/06.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
Abbott Laboratories Hedge Fund Activity
We have seen 1,299 institutional investors add shares of Abbott Laboratories stock to their portfolio, and 1,658 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- J. STERN & CO. LLP added 39,005,451 shares (+12439.6%) to their portfolio in Q4 2025, for an estimated $4,886,992,955
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 30,767,022 shares (-73.6%) from their portfolio in Q4 2025, for an estimated $3,854,800,186
- JPMORGAN CHASE & CO removed 7,190,072 shares (-24.5%) from their portfolio in Q4 2025, for an estimated $900,844,120
- ALLIANCEBERNSTEIN L.P. added 6,926,031 shares (+125.3%) to their portfolio in Q4 2025, for an estimated $867,762,423
- BLACKROCK, INC. added 5,348,812 shares (+3.8%) to their portfolio in Q4 2025, for an estimated $670,152,655
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 4,993,343 shares (-28.1%) from their portfolio in Q4 2025, for an estimated $625,615,944
- POLEN CAPITAL MANAGEMENT LLC removed 3,458,374 shares (-46.6%) from their portfolio in Q4 2025, for an estimated $433,299,678
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Abbott Laboratories Government Contracts
We have seen $121,058,922 of award payments to $ABT over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- VISN 9 CHEMISTRY AUTOMATION COST PER RESULTS REPORTABLE: $4,699,622
- VISN1 BPA FOR IMMUNOCHEMISTRY CPRR TESTING ADDING EQUIPMENT FOR MANCHESTER NH VAMC - WITHIN ORIGINAL SCOPE: $4,335,000
- CHEMISTRY IMMUNOASSAY ANALYZER COST PER REPORTABLE RESULT (CPRR) PRICE SCHEDULE UPDATE: $4,000,483
- EXERCISING OPTION YEAR 2: $2,600,297
- CHEMISTRY ANALYZERS.: $2,351,823
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
Abbott Laboratories Analyst Ratings
Wall Street analysts have issued reports on $ABT in the last several months. We have seen 7 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Barclays issued a "Overweight" rating on 02/02/2026
- BTIG issued a "Buy" rating on 01/23/2026
- RBC Capital issued a "Outperform" rating on 10/16/2025
- Wells Fargo issued a "Overweight" rating on 10/16/2025
- Raymond James issued a "Outperform" rating on 10/16/2025
- Evercore ISI Group issued a "Outperform" rating on 10/16/2025
- Benchmark issued a "Buy" rating on 10/10/2025
To track analyst ratings and price targets for Abbott Laboratories, check out Quiver Quantitative's $ABT forecast page.
Abbott Laboratories Price Targets
Multiple analysts have issued price targets for $ABT recently. We have seen 11 analysts offer price targets for $ABT in the last 6 months, with a median target of $140.0.
Here are some recent targets:
- Matt Miksic from Barclays set a target price of $142.0 on 02/02/2026
- Joanne Wuensch from Citigroup set a target price of $140.0 on 01/23/2026
- Shagun Singh from RBC Capital set a target price of $135.0 on 01/23/2026
- Lee Hambright from Bernstein set a target price of $125.0 on 01/23/2026
- Adam Maeder from Piper Sandler set a target price of $135.0 on 01/23/2026
- Marie Thibault from BTIG set a target price of $140.0 on 01/23/2026
- Suraj Kalia from Oppenheimer set a target price of $132.0 on 01/23/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
